CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
stocks
Impact of ANZ’s huge fine
stocks
Acquisition a sign of weakness for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,117.50 | 5.00 | -0.05% |
CAC 40 | 7,818.22 | 78.71 | -1.00% |
DAX 40 | 23,329.24 | 419.62 | -1.77% |
Dow JONES (US) | 45,757.90 | 125.55 | -0.27% |
FTSE 100 | 9,195.66 | 81.37 | -0.88% |
HKSE | 26,438.51 | 8.05 | -0.03% |
NASDAQ | 22,333.96 | 14.79 | -0.07% |
Nikkei 225 | 44,821.03 | 81.24 | -0.18% |
NZX 50 Index | 13,166.69 | 68.20 | -0.52% |
S&P 500 | 6,606.76 | 8.52 | -0.13% |
S&P/ASX 200 | 8,841.70 | 6.80 | -0.08% |
SSE Composite Index | 3,859.56 | 2.30 | -0.06% |